Prevalence and prognosis of Alzheimer’s disease at the mild cognitive impairment stage
Open Access
- 17 February 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in Brain
- Vol. 138 (5), 1327-1338
- https://doi.org/10.1093/brain/awv029
Abstract
Three sets of research criteria are available for diagnosis of Alzheimer’s disease in subjects with mild cognitive impairment: the International Working Group-1, International Working Group-2, and National Institute of Aging-Alzheimer Association criteria. We compared the prevalence and prognosis of Alzheimer’s disease at the mild cognitive impairment stage according to these criteria. Subjects with mild cognitive impairment (n = 1607), 766 of whom had both amyloid and neuronal injury markers, were recruited from 13 cohorts. We used cognitive test performance and available biomarkers to classify subjects as prodromal Alzheimer’s disease according to International Working Group-1 and International Working Group-2 criteria and in the high Alzheimer’s disease likelihood group, conflicting biomarker groups (isolated amyloid pathology or suspected non-Alzheimer pathophysiology), and low Alzheimer’s disease likelihood group according to the National Institute of Ageing-Alzheimer Association criteria. Outcome measures were the proportion of subjects with Alzheimer’s disease at the mild cognitive impairment stage and progression to Alzheimer’s disease-type dementia. We performed survival analyses using Cox proportional hazards models. According to the International Working Group-1 criteria, 850 (53%) subjects had prodromal Alzheimer’s disease. Their 3-year progression rate to Alzheimer’s disease-type dementia was 50% compared to 21% for subjects without prodromal Alzheimer’s disease. According to the International Working Group-2 criteria, 308 (40%) subjects had prodromal Alzheimer’s disease. Their 3-year progression rate to Alzheimer’s disease-type dementia was 61% compared to 22% for subjects without prodromal Alzheimer’s disease. According to the National Institute of Ageing-Alzheimer Association criteria, 353 (46%) subjects were in the high Alzheimer’s disease likelihood group, 49 (6%) in the isolated amyloid pathology group, 220 (29%) in the suspected non-Alzheimer pathophysiology group, and 144 (19%) in the low Alzheimer’s disease likelihood group. The 3-year progression rate to Alzheimer’s disease-type dementia was 59% in the high Alzheimer’s disease likelihood group, 22% in the isolated amyloid pathology group, 24% in the suspected non-Alzheimer pathophysiology group, and 5% in the low Alzheimer’s disease likelihood group. Our findings support the use of the proposed research criteria to identify Alzheimer’s disease at the mild cognitive impairment stage. In clinical settings, the use of both amyloid and neuronal injury markers as proposed by the National Institute of Ageing-Alzheimer Association criteria offers the most accurate prognosis. For clinical trials, selection of subjects in the National Institute of Ageing-Alzheimer Association high Alzheimer’s disease likelihood group or the International Working Group-2 prodromal Alzheimer’s disease group could be considered.Keywords
This publication has 30 references indexed in Scilit:
- Injury markers predict time to dementia in subjects with MCI and amyloid pathologyNeurology, 2012
- An operational approach to National Institute on Aging–Alzheimer's Association criteria for preclinical Alzheimer diseaseAnnals of Neurology, 2011
- Diagnostic and Statistical Manual of Mental DisordersPsychiatry Research, 2011
- Data mining methods in the prediction of Dementia: A real-data comparison of the accuracy, sensitivity and specificity of linear discriminant analysis, logistic regression, neural networks, support vector machines, classification trees and random forestsBMC Research Notes, 2011
- Lack of Accuracy for the Proposed ‘Dubois Criteria’ in Alzheimer’s Disease: A Validation Study from the Swedish Brain Power InitiativeDementia and Geriatric Cognitive Disorders, 2010
- New Research Criteria for the Diagnosis of Alzheimer’s Disease Applied in a Memory Clinic PopulationDementia and Geriatric Cognitive Disorders, 2010
- Combination of Hippocampal Volume and Cerebrospinal Fluid Biomarkers Improves Predictive Value in Mild Cognitive ImpairmentDementia and Geriatric Cognitive Disorders, 2010
- Early and Differential Diagnosis of Dementia and Mild Cognitive ImpairmentDementia and Geriatric Cognitive Disorders, 2009
- Development of Screening Guidelines and Clinical Criteria for Predementia Alzheimer’s DiseaseNeuroepidemiology, 2008
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984